Trials / Completed
CompletedNCT00504426
Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 101 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- Female
- Age
- 46 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine the efficacy and safety of OPC-249 by once daily inhalation at 0 (placebo), 30, 60 or 120 IU for 4 weeks in patients with pain due to osteoporosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OPC-249 | 1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU) |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2008-07-01
- Completion
- 2009-05-01
- First posted
- 2007-07-20
- Last updated
- 2014-01-30
- Results posted
- 2014-01-30
Locations
5 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00504426. Inclusion in this directory is not an endorsement.